within Pharmacolibrary.Drugs.ATC.N;

model N07CA52
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.75,
    Cl             = 0.0006666666666666666,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.1,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0038333333333333336,
    Tlag           = 1800
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N07CA52</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Cinnarizine is a selective calcium channel blocker and antihistamine, commonly indicated for the treatment of vestibular disorders such as vertigo, motion sickness, and balance disorders. Combinations (ATC code N07CA52) often refer to formulations with dimenhydrinate to enhance anti-vertigo efficacy. While cinnarizine is used in several countries, its regulatory approval and usage status may vary globally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic estimates for cinnarizine in fixed-dose combination with dimenhydrinate in healthy adult volunteers.</p><h4>References</h4><ol><li><p>Berlin, M, et al., &amp; Dressman, JB (2014). Prediction of oral absorption of cinnarizine--a highly supersaturating poorly soluble weak base with borderline permeability. <i>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</i> 88(3) 795–806. DOI:<a href=&quot;https://doi.org/10.1016/j.ejpb.2014.08.011&quot;>10.1016/j.ejpb.2014.08.011</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25195981/&quot;>https://pubmed.ncbi.nlm.nih.gov/25195981</a></p></li><li><p>Kesharwani, SS, &amp; Ibrahim, F (2023). A Combined In-Vitro and GastroPlus® Modeling to Study the Effect of Intestinal Precipitation on Cinnarizine Plasma Profile in a Fasted State. <i>AAPS PharmSciTech</i> 24(5) 121–None. DOI:<a href=&quot;https://doi.org/10.1208/s12249-023-02577-w&quot;>10.1208/s12249-023-02577-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37173520/&quot;>https://pubmed.ncbi.nlm.nih.gov/37173520</a></p></li><li><p>Nachum, Z, et al., &amp; Gordon, CR (2006). Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. <i>Clinical pharmacokinetics</i> 45(6) 543–566. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200645060-00001&quot;>10.2165/00003088-200645060-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16719539/&quot;>https://pubmed.ncbi.nlm.nih.gov/16719539</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N07CA52;
